Germ Cell Tumours: What we have learned from MaGIC and how this model of collaboration can apply to other cancers
James Nicholson, UK
Increasing Enrollment of Adolescents and Young Adults with Cancer in Clinical Trials
David Freyer, USA
Identifying cells of origin
Sam Behjati, UK
Brain tumors in infants
Stefan Rutkowski, Germany
Biomarker development including circulating tumor cells and cell free DNA
Brian Crompton, USA
D’angio lecture -Genomic guided radiotherapy for children : a new Era ?
Anita Mahajan,USA
Endocrine Tumors (IPSO)
Paul Losty, UK
Therapeutic opportunities for cancer predisposition syndromes
David Malkin, Canada
The imperative to listen to the child’s voice in pediatric oncology
Ulrika Kreicbergs, Sweden
1.Addressing mental health across the cancer trajectory
Convener: Gisela Michel, Switzerland
Screening for mental health problems in childhood cancer survivorship
Gisela Michel, Switzerland
Mental health care needs in childhood cancer patients and survivors
Jordan Gilleland Marchak, USA
Mental health of childhood cancer patients and survivors during the COVID-19 pandemic
Fiona Schulte, Canada
2. Generating intelligence from data with advanced analytics including machine learning
Convener: Lillian Sung, Canada
Introduction to Machine Learning – What it is and What it Isn’t?
Lillian Sung, Canada
Application of Machine Learning in the Hospital Setting
David Scheinker, USA
Application of Machine Learning in Public Health and Health Systems
Laura Rosella, Canada
3.Immunotherapies for solid tumors
Convener: Claudia Rossig, Germany
Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma
Lenid Metelitsa, USA
Strategies for overcoming escape from CAR T cell targeting in pediatric solid cancers
Claudia Rossig, Germany
Combining antitumor antibodies with CD47 „don´t eat me“ blockade for immunotherapy of neuroblastoma and childhood sarcomas
Robbie Majzner, USA
4. Major Issues in Peadiatric Cancer Survivorship
Convener: Melissa Hudson, USA
Evolving patterns of cancer treatment-related morbidity
Melissa Hudson, USA
Progress in characterizing reproductive health risks and fertility preservation
Treatment and genetic factors underlying risks for subsequent malignant neoplasm
Lucie Turcotte, USA
5. PROS Symposium : Management of Craniopharyngioma
Radiotherapy Management of Craniopharyngioma
Beate Timmerman, Germany
Surgical Management
Robert Buckley, USA
Medical management , pediatrician point of view
Gesina Keating, USA
6. Implementation and results of SIOP PODC adapted treatment guidelines in low income countries
Convener: Trijn Israels, The Netherlands
Global implementation and results of SIOP PODC Adapted Treatment Guidelines
Ramandeep Arora, India
The Collaborative Wilms Tumour Africa Project – use and results of a SIOP PODC adapted treatment guideline
Vivian Paintsil, Ghana
Adapted treatment guidelines in sub-Saharan Africa – lessons learned and the way forward
Trijn Israels, The Netherlands
7. SIOP/PROS/IPSO symposium-Multidisciplinary management of pelvic tumors
Convener: Andrea Hayes-Jordan, USA
Surgical approach for pelvic sarcomas, what´s new?
Andrea Hayes-Jordan, USA
Rrhabdo and Non-Rhabdo Pelvic Sarcoma: point of view of the radiation oncologist
Normand Laperriere, Canada
The management of bladder/prostate, vaginal and “other” rhabdomyosarcomas of the pelvis
Rajkumar Venkatramani, USA
8. Tyrosine Kinase Inhibitor Therapy: Beyond ABL Inhibition
Convener: Andrea Biondi, Italy
Ph+ ALL: Current International Clinical Trial and Future Directions
Andrea Biondi, Italy
Ph+ALL: Two Decades Experiences with Tyrosine Kinase Inhibitor
Lewis Silverman, USA
CML: What Do We Want to Know?
Kirk Schultz, Canada
9. St. Baldrick’s Lecture:Biological insights and how they inform targeted therapies in Hodgkin lymphoma
Convener: Monica Metzger, USA
Biological targets and biomarkers in Hodgkin lymphoma
Christian Steidl, Canada
Imaging and biologic biomarkers to guide tailored therapy in pediatric Hodgkin lymphoma
Christine Mauz-Körholz, Germany
Translation of targeted therapy into pediatric frontline clinical trials for Hodgkin lymphoma
Monica Metzger, USA
Choosing the ideal immunotherapy in ALL
Convenor: Andre Baruchel, France
Best treatment for relapsed ALL : the place of bispecific and HSCT
Patrick Brown, USA
Best treatment for relapsed ALL : the place of CAR-T cells
Rebecca Gardner, USA
The ideal immunotherapy of ALL : a tentative synthesis
Andre Baruchel, France
Is there still a role for stem cell transplantation in neuroblastoma
Convenor: Jaume Mora, Spain
Is there still a role for stem cell transplantation in neuroblastoma? YES
Is there still a role for stem cell transplantation in neuroblastoma? NO
Shakeel Modak, USA
Perspective and Consequences Worldwide
Jaume Mora, Spain
Current knowledge in Osteosarcoma
Richard Gorlick, USA
The emerging role of child centered care – should it replace family centered care?
Inger Kristensson Hallström, Sweden
Everything you wanted to know about advanced molecular classification in pediatric brain tumors
Michael Taylor, Canada